Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Abana CO"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-5 z 5
    Tytuł:
    Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma.
    Autorzy:
    Manzar GS; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
    De BS; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
    Abana CO; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
    Lee SS; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
    Javle M; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
    Kaseb AO; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
    Vauthey JN; Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
    Tran Cao HS; Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
    Koong AC; Department of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
    Smith GL; Department of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
    Taniguchi CM; Department of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
    Holliday EB; Department of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
    Das P; Department of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
    Koay EJ; Department of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
    Ludmir EB; Department of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
    Pokaż więcej
    Źródło:
    Cancers [Cancers (Basel)] 2022 Apr 09; Vol. 14 (8). Date of Electronic Publication: 2022 Apr 09.
    Typ publikacji:
    Journal Article
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    A radioenhancing nanoparticle mediated immunoradiation improves survival and generates long-term antitumor immune memory in an anti-PD1-resistant murine lung cancer model.
    Autorzy:
    Hu Y; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 6565 MD Anderson Boulevard, Houston, TX, 77030, USA.
    Paris S; Department of Translational Science, Nanobiotix, Paris, France.
    Barsoumian H; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 6565 MD Anderson Boulevard, Houston, TX, 77030, USA.
    Abana CO; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 6565 MD Anderson Boulevard, Houston, TX, 77030, USA.
    He K; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 6565 MD Anderson Boulevard, Houston, TX, 77030, USA.; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
    Sezen D; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 6565 MD Anderson Boulevard, Houston, TX, 77030, USA.; Department of Radiation Oncology, Koc University School of Medicine, Istanbul, Turkey.
    Wasley M; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 6565 MD Anderson Boulevard, Houston, TX, 77030, USA.
    Masrorpour F; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 6565 MD Anderson Boulevard, Houston, TX, 77030, USA.
    Chen D; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
    Yang L; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 6565 MD Anderson Boulevard, Houston, TX, 77030, USA.
    Dunn JD; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 6565 MD Anderson Boulevard, Houston, TX, 77030, USA.
    Gandhi S; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 6565 MD Anderson Boulevard, Houston, TX, 77030, USA.
    Nguyen QN; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 6565 MD Anderson Boulevard, Houston, TX, 77030, USA.
    Cortez MA; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 6565 MD Anderson Boulevard, Houston, TX, 77030, USA.
    Welsh JW; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 6565 MD Anderson Boulevard, Houston, TX, 77030, USA. .
    Pokaż więcej
    Źródło:
    Journal of nanobiotechnology [J Nanobiotechnology] 2021 Dec 11; Vol. 19 (1), pp. 416. Date of Electronic Publication: 2021 Dec 11.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Lung Neoplasms*/mortality
    Lung Neoplasms*/pathology
    Radiation-Sensitizing Agents*/chemistry
    Radiation-Sensitizing Agents*/pharmacology
    Immune Checkpoint Inhibitors/*pharmacology
    Immunologic Memory/*drug effects
    Nanoparticles/*chemistry
    Animals ; Drug Resistance, Neoplasm ; Female ; Mice ; Neoplasms, Experimental ; Radioimmunotherapy
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    IL-6 variant is associated with metastasis in breast cancer patients.
    Autorzy:
    Abana CO; Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
    Bingham BS; Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
    Cho JH; Department of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States of America.
    Graves AJ; Department of Urologic Surgery and Center for Quantitative Science, Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.; Center for Quantitative Science, Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
    Koyama T; Center for Quantitative Science, Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
    Pilarski RT; Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.
    Chakravarthy AB; Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
    Xia F; Department of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.
    Pokaż więcej
    Źródło:
    PloS one [PLoS One] 2017 Jul 21; Vol. 12 (7), pp. e0181725. Date of Electronic Publication: 2017 Jul 21 (Print Publication: 2017).
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Breast Neoplasms/*genetics
    Genetic Predisposition to Disease/*genetics
    Interleukin-6/*genetics
    Polymorphism, Single Nucleotide/*genetics
    Aged ; Aged, 80 and over ; Alleles ; Case-Control Studies ; Female ; Gene Frequency/genetics ; Genotype ; Humans ; Male ; Middle Aged ; Ohio ; Promoter Regions, Genetic/genetics ; Risk Factors
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Erratum to: HIV integration sites in latently infected cell lines: evidence of ongoing replication.
    Autorzy:
    Symons J; The Peter Doherty Institute for Infection and Immunity, University of Melbourne and Royal Melbourne Hospital, 792 Elizabeth St, Melbourne, VIC, 3000, Australia.
    Chopra A; Institute for Immunology and Infectious Diseases (IIID), Murdoch University, Murdoch, WA, Australia.
    Malatinkova E; HIV Translational Research Unit, Department of Internal Medicine, Faculty of Medicine and Health Sciences, Ghent University Hospital, Ghent University, Ghent, Belgium.
    De Spiegelaere W; HIV Translational Research Unit, Department of Internal Medicine, Faculty of Medicine and Health Sciences, Ghent University Hospital, Ghent University, Ghent, Belgium.
    Leary S; Institute for Immunology and Infectious Diseases (IIID), Murdoch University, Murdoch, WA, Australia.
    Cooper D; Institute for Immunology and Infectious Diseases (IIID), Murdoch University, Murdoch, WA, Australia.
    Abana CO; Department of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, TN, 37232, USA.
    Rhodes A; The Peter Doherty Institute for Infection and Immunity, University of Melbourne and Royal Melbourne Hospital, 792 Elizabeth St, Melbourne, VIC, 3000, Australia.
    Rezaei SD; The Peter Doherty Institute for Infection and Immunity, University of Melbourne and Royal Melbourne Hospital, 792 Elizabeth St, Melbourne, VIC, 3000, Australia.
    Vandekerckhove L; HIV Translational Research Unit, Department of Internal Medicine, Faculty of Medicine and Health Sciences, Ghent University Hospital, Ghent University, Ghent, Belgium.
    Mallal S; Institute for Immunology and Infectious Diseases (IIID), Murdoch University, Murdoch, WA, Australia.; Department of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, TN, 37232, USA.
    Lewin SR; The Peter Doherty Institute for Infection and Immunity, University of Melbourne and Royal Melbourne Hospital, 792 Elizabeth St, Melbourne, VIC, 3000, Australia.; Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia.
    Cameron PU; The Peter Doherty Institute for Infection and Immunity, University of Melbourne and Royal Melbourne Hospital, 792 Elizabeth St, Melbourne, VIC, 3000, Australia. .; Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia. .
    Pokaż więcej
    Źródło:
    Retrovirology [Retrovirology] 2017 Mar 27; Vol. 14 (1), pp. 23. Date of Electronic Publication: 2017 Mar 27.
    Typ publikacji:
    Journal Article; Published Erratum
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    HIV integration sites in latently infected cell lines: evidence of ongoing replication.
    Autorzy:
    Symons J; The Peter Doherty Institute for Infection and Immunity, University of Melbourne and Royal Melbourne Hospital, 792 Elizabeth St, Melbourne, VIC, 3000, Australia.
    Chopra A; Institute for Immunology and Infectious Diseases (IIID), Murdoch University, Murdoch, WA, Australia.
    Malatinkova E; HIV Translational Research Unit, Department of Internal Medicine, Faculty of Medicine and Health Sciences, Ghent University Hospital, Ghent University, Ghent, Belgium.
    De Spiegelaere W; HIV Translational Research Unit, Department of Internal Medicine, Faculty of Medicine and Health Sciences, Ghent University Hospital, Ghent University, Ghent, Belgium.
    Leary S; Institute for Immunology and Infectious Diseases (IIID), Murdoch University, Murdoch, WA, Australia.
    Cooper D; Institute for Immunology and Infectious Diseases (IIID), Murdoch University, Murdoch, WA, Australia.
    Abana CO; Department of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, TN, 37232, USA.
    Rhodes A; The Peter Doherty Institute for Infection and Immunity, University of Melbourne and Royal Melbourne Hospital, 792 Elizabeth St, Melbourne, VIC, 3000, Australia.
    Rezaei SD; The Peter Doherty Institute for Infection and Immunity, University of Melbourne and Royal Melbourne Hospital, 792 Elizabeth St, Melbourne, VIC, 3000, Australia.
    Vandekerckhove L; HIV Translational Research Unit, Department of Internal Medicine, Faculty of Medicine and Health Sciences, Ghent University Hospital, Ghent University, Ghent, Belgium.
    Mallal S; Institute for Immunology and Infectious Diseases (IIID), Murdoch University, Murdoch, WA, Australia.; Department of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, TN, 37232, USA.
    Lewin SR; The Peter Doherty Institute for Infection and Immunity, University of Melbourne and Royal Melbourne Hospital, 792 Elizabeth St, Melbourne, VIC, 3000, Australia.; Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia.
    Cameron PU; The Peter Doherty Institute for Infection and Immunity, University of Melbourne and Royal Melbourne Hospital, 792 Elizabeth St, Melbourne, VIC, 3000, Australia. .; Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia. .
    Pokaż więcej
    Źródło:
    Retrovirology [Retrovirology] 2017 Jan 13; Vol. 14 (1), pp. 2. Date of Electronic Publication: 2017 Jan 13.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Virus Integration*
    Virus Latency*
    Virus Replication*
    HIV/*physiology
    Cell Line ; High-Throughput Nucleotide Sequencing/methods ; Humans
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
      Wyświetlanie 1-5 z 5

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies